- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04842422
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream:
The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 8010
- Universitätsklinik für Dermatologie und Venerologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion
- Male and female supposed-healthy volunteer outpatients, age: > 50 years.
- Diagnosis: patients with chronically UV-exposed photodamaged facial skin.
- Consent by signing the ICF (Informed Consent Form)
Exclusion
- Current participation in another clinical trial
- Patients who are using topical glucocorticoids on the face.
- Known intolerance/hypersensitivity to imiquimod
- Pregnant/breastfeeding women
- Systemic disease, immunodeficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Earliest Stage Treatment of Aktinic Keratosis
|
Imiquimod 3.75% Cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
immunomodulatory-induced inflammatory reaction
Time Frame: two weeks
|
Percentage of subjects in whom an immunomodulatory-induced inflammatory reaction occurs on chronically light-exposed uv-damaged facial skin after two weeks.
|
two weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratoses
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
-
PeplinCompleted
Clinical Trials on Imiquimod 3.75% Cream
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Taro Pharmaceuticals USACompleted
-
Medicis Global Service CorporationUnknownActinic KeratosisUnited States
-
Actavis Mid-Atlantic LLCCompleted
-
Teva Pharmaceuticals USACompletedActinic KeratosisUnited States
-
Icahn School of Medicine at Mount SinaiBausch Health Americas, Inc.CompletedActinic KeratosisUnited States
-
Rochester General HospitalBausch Health Americas, Inc.; Rochester Skin Lymphoma Medical Group, PLLCWithdrawn
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States
-
Graceway Pharmaceuticals, LLCCompletedKeratosisUnited States